Journal Mobile Options
Table of Contents
Vol. 42, No. 1, 2000
Issue release date: June 2000

(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies

McCann U.D. · Eligulashvili V. · Ricaurte G.A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

(±)3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) is a brain serotonergic neurotoxin in experimental animals, including nonhuman primates. It is also an increasingly popular recreational drug of abuse, and doses of MDMA that are used recreationally overlap with those that produce serotonin (5-HT) neurotoxicity in animals. Studies in human MDMA users probing for evidence of brain serotonergic neurotoxicity indicate that some MDMA users may incur MDMA-related 5-HT neural injury and, possibly, functional sequelae. In particular, MDMA users have selective decrements in cerebrospinal fluid 5-hydroxyindoleacetic acid and brain 5-HT transporters, similar to nonhuman primates with documented MDMA-induced neurotoxicity. Functional abnormalities seen in MDMA users that may be related to 5- HT injury include cognitive deficits, altered sleep architecture, altered neuroendocrine function, altered behavioral responses to 5-HT selective drugs, and increased impulsivity. Additional studies in animals, as well as longitudinal and epidemiological studies in MDMA users, are required to confirm and extend the present data, and to determine whether MDMA users are at increased risk for developing neuropsychiatric illness as they age.

Copyright © 2000 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Ricaurte GA, Yuan J, McCann UD: (±)3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)-induced serotonin neurotoxicity: Studies in animals. Neuropsychobiology 2000;42:5–10.
  2. Ricaurte GA, Delanney LE, Wiener SG, Irwin I, Langston JW:5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in the CNS of non-human primates. Brain Res 1988;474:359–363.
  3. Ricaurte GA, Finnegan KT, Irwin I, Langston JW: Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary observations. Ann N Y Acad Sci 1990;600:699–710.
  4. Peroutka SJ, Pascoe N, Faull KF: Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Res Comm Substance Abuse 1987;8:125–138.
  5. Post RM, Ballenger JC, Goodwin FK: Cerebrospinal fluid studies of neurotransmitter function in manic and depressive illness; in Wood JH (ed): Neurobiology of Cerebrospinal Fluid. New York, Plenum Press, 1980, pp 685–717.
  6. Brewerton TD, Berrettini WH, Nurnberger JI, Linnoila M: Analysis of seasonal fluctuations of CSF monoamine metabolites and neuropeptides in normal controls: Findings with 5-HIAA and HVA. Psychiatry Res 1987;23:257–265.

    External Resources

  7. Bertilsson L, Asberg M, Lantto O, Scalia-Tomba G, Traskman-Bendz L, Tybring G: Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls. Psychiatry Res 1982;6:77–83.
  8. McCann UD, Ridenour A, Shaham Y, Ricaurte GA: Brain serotonergic neurotoxicity after MDMA (‘Ecstasy’): A controlled study in humans. Neuropsychopharmacology 1994;10:129–138.
  9. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA: Cognitive performance in (±)3,4- methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users: A controlled study. Psychopharmacology 1999;143:417–425.
  10. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA: In vivo detection of short- and long-term MDMA neurotoxicity: A positron emission tomography study in the living baboon brain. Synapse 1998;29:183–192.
  11. Kerenyi LL, Szabo Z, Scheffel U, Matthews WB, Ravert HT, Szabo K, Dannals RF, Ricaurte GA: Assessment of serotonergic innervation with [C-11] McN5652/PET. Soc Nucl Med 1999;40:115.
  12. McCann UD, Szabo Z, Scheffel U, Matthews WB, Dannals RF, Ravert HT, Musachio JL, Mertl MM, Ricaurte GA: Positron tomographic evidence of toxic effect of MDMA (‘Ecstasy’) on brain serotonin neurons in human beings. Lancet 1998;352:1433–1437.
  13. Ricaurte GA, Sabol KE, Seiden LS: Functional consequences of neurotoxic amphetamine exposure; in Cho AK, Segal DS (eds): Amphetamine and Its Analogs. San Diego, Academic Press, 1994, pp 297–313.
  14. Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, Woods SW, Heninger GR: Clinical studies of 5-HT function using i.v. L-Tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:459–472.
  15. Kato Y, Nakai Y, Imura H, Chihara K, Ogo S: Effect of cyproheptadine on 5-hydroxytryptophan on plasma prolactin levels in man. J Clin Endocrinol Metab 1974;38:696–703.
  16. Kuhn CM, Vogel RA, Mailman RB Mueller RA, Schanberg SM, Breese GR: Effect of 5,7-DHT on serotonergic control of prolactin secretion and behavior in rats. Psychopharmacology 1981;73:188–193.
  17. Price LH, Ricaurte GA, Krystal J, Heninger G: Neuroendocrine and mood responses to intravenous L-tryptophan in (±)3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen Psychiatry 1989;46:20–22.

    External Resources

  18. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R, Caccavari R, Delsignore R: Serotonergic function after (±)3,4-methylenedioxymethamphetamine (‘Ecstasy’) in humans. Int Clin Psychopharmacol 1998;13:1–9.
  19. McCann UD, Mertl MM, Murphy DL, Post RP, Ricaurte GA: Neuroendocrine effects of intravenous metachlorophenylpiperazine in (±)3,4-methylenedioxymethamphetamine users. American Psychiatric Association New Research Program and Abstracts 1997, p147.
  20. Ricaurte GA, Martello AL, Katz JL, Martello MB: Lasting effects of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates: Neurochemical observations. J Pharmacol Exp Ther 1992;261:616–622.

    External Resources

  21. Fischer CA, Hatzidimitriou G, Katz JL, Ricaurte GA: Reorganization of ascending serotonin axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphetamine. J Neurosci 1995;15:5476–5485.

    External Resources

  22. Berendsen HHG, Broekamp CLE, Van Delft AML: Denervation supersensitivity of 5HT1C – but not of 5HT1A – and 5HT1. Psychopharmacology 1990;101(suppl):55.
  23. Lucki I, Ward HR, Frazer A: Effect of 1-(m-chlorophenyl)piperazine and 1-m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 1989;249:155–164.
  24. Quattrone A, Schettini G, Annunziato L, Di Renzo G: Pharmacological evidence of supersensitivity of central serotonergic receptors involved in the control of prolactin secretion. Eur J Pharmacol 1981;76:9–13.
  25. Murphy DL, Lesch KP, Aulakh CS, Pigott TA: Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature and cardiovascular effects in humans. Pharmacol Rev 1991;43:527–552.
  26. Eriksson E, Engberg G, Bing O, Nissbrandt H: Effects of mCPP on the extracellular concentrations of serotonin and dopamine in the rat brain. Neuropsychopharmacology 1999;20:287–296.
  27. Charney DS, Woods SW, Goodman WK, Henninger GR: Serotonin function in anxiety. II. Effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Arch Gen Psychiatry 1987;45:177–185.
  28. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder: Comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946–951.
  29. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function. Am J Drug Alcohol Abuse 1992;18:331–341.
  30. Parrot AC, Lees A, Granham NJ, Jones M, Wesnes K: Cognitive performance in recreational users of MDMA or ‘ecstasy’: Evidence for memory deficits. J Psychopharmacol 1998;12:79–83.
  31. Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacology 1998;139:261–268.
  32. Bolla KI, McCann UD, Ricaurte GA: Impaired memory function in abstinent MDMA (‘Ecstasy’) users. Neurology 1998;51:1532–1537.
  33. Morgan MM: Memory deficits associated with recreational use of ‘ecstasy’ (MDMA). Psychopharmacology 1999;141:30–36.
  34. Jones BE: Basic mechanisms of sleep; in Kryger MH, Roth T, Dement WC (eds): Principles and Practice of Sleep Medicine. Philadelphia, Saunders, 1989, pp 121–141.
  35. Hartmann E, Cravens J, List S: Hypnotic effects of L-tryptophan. Arch Gen Psychiatry 1974;31:394–397.

    External Resources

  36. Griffiths WJ, Lester BK, Coulter JD, Williams HL: Tryptophan and sleep in young adults. Psychophysiology 1972;9:345–356.

    External Resources

  37. Brown CC, Horrom NJ, Wagman AMI: Effects of L-tryptophan on sleep onset insomniacs. Waking Sleeping 1979;3:101–108.

    External Resources

  38. Allen R, McCann UD, Ricaurte GA: Sleep in abstinent users of MDMA. Sleep 1993;16:560–564.
  39. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF: Aggression in humans correlates with cerebrospinal fluid metabolites. Psychiatry Res 1979;1:131–139.
  40. Coccaro EF: Central serotonin and impulsive aggression. Br J Psychiatry 1989;155:52–62.
  41. Buss AH, Durkee A: An inventory for assessing different kinds of hostility. J Consult Psychol 1957;21:343–349.
  42. Tellegen A: Multidimensional Personality Questionaire. Copyright by Auke Tellegen, 1982.
  43. Morgan MJ: Recreational use of ‘Ecstasy’ (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1989;19:252–264.
  44. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend 1999;55:105–115.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50